Therapeutic efficiency of amphotericin B liposome modified by RMP-7 to transport drug across blood brain barrier.
- Author:
Xiao-bin ZHANG
1
;
Shan YUAN
;
Peng-cheng LEI
;
Xin-pu HOU
Author Information
- Publication Type:Journal Article
- MeSH: Amphotericin B; administration & dosage; pharmacokinetics; therapeutic use; Animals; Antifungal Agents; administration & dosage; pharmacokinetics; therapeutic use; Biological Transport; Blood-Brain Barrier; drug effects; Bradykinin; analogs & derivatives; pharmacology; Brain; metabolism; Candida albicans; Drug Delivery Systems; Female; Liposomes; Male; Meningitis, Fungal; drug therapy; microbiology; Mice; Mice, Inbred BALB C; Rats; Rats, Sprague-Dawley
- From: Acta Pharmaceutica Sinica 2004;39(4):292-295
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo study the therapeutic efficiency of amphotericin B liposome (AmB-L) targeting to the brain in mice with meningitis.
METHODSAmphotericin B liposome targeting to the brain were prepared by film-sonication method. Their concentration and encapsulation percentage were determined. The Candida albicans was injected into the brain of BALB/c mice and the meningitis model was set up. Then the therapeutic efficiency of amphotericin B liposome targeting to the brain was studied.
RESULTSThe encapsulation percentage of amphotericin B liposome was 93.3%. The meningitis model was set up after the Candida albicans was injected into the brain of BALB/c mice for 2 h. The therapeutic efficiency was increased after conjugating RMP-7 (the commercial nama is Cereport) to the surface of amphotericin B liposome.
CONCLUSIONThe therapeutic efficiency of Amphotericin B liposome targeting to the brain in the mice with meningitis was better than that of the common amphotericin B liposome and the life of the mice in AmB-L-PEG-RMP-7 group was longer than that of the mice in AmB-L-PEG group and AmB-L-PEG + RMP-7 group.
